https://www.selleckchem.com/pr....oducts/gsk-3008348-h
19, 95% CI 0.93 to 1.53; I2 0%; very low certainty) or at maximal follow-up (RR 1.03, 95% CI 0.89 to 1.21; I2 0%; very low certainty). We found evidence against an effect on quality of life at maximal follow-up. The proportion of patients with at least one serious adverse event did not differ at end of intervention or at maximal follow-up. For most comparisons, TSA suggested that further trials are needed. We found no evidence of a difference between early mobilisation versus standard care for patients with severe acqu
Like
Comment
Share
